RemeGenix, Inc (RGX) is a biopharmaceutical company located in Maryland specializing in the development and commercialization of therapies for neurodegenerative diseases. Specifically, RGX is focused on the commercializing technologies that treat the cause of the disease versus the symptoms.  

Established in 2006, the Company is led by a strong management team, and has rapidly developed a complementary product pipeline with numerous expansion markets. The technology in its portfolio was selected for focus on neurodegenerative disease, but also for the quantity and quality of scientific validation in each of the products.  

Collectively the management team and advisory boards consists of experienced business, regulatory, and intellectual property executives, along with world renowned scientists specializing in molecular biology, neuroscience, medicinal chemistry and cognition.   

The company's primary focus area of neurodegenerative disease is one of the largest therapeutic sectors in biotechnology with much of the market being left clinically unmet. In line with this rapidly expanding market, RemeGenix product candidates can be used to address a wide range of neurodegenerative conditions including Alzheimer's disease, brain injury, stroke, and dementia.